A Novel Approach to Safer Analgesics: Mu Opioid Receptor Agonist & Delta Opioid Receptor Antagonist Peptidomimetics

Novel Approach ◽

Modulation of Gastrointestinal Function by MuDelta, a mixed Mu Opioid Receptor Agonist/Delta Opioid Receptor Antagonist

The FASEB Journal ◽

10.1096/fasebj.26.1_supplement.lb766 ◽

2012 ◽

Vol 26 (S1) ◽

Author(s):

Pamela J Hornby

Keyword(s):

Receptor Antagonist ◽

Opioid Receptor ◽

Receptor Agonist ◽

Mu Opioid Receptor ◽

Delta Opioid Receptor ◽

Gastrointestinal Function ◽

Mu Opioid ◽

Faculty Opinions recommendation of Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1086845.539776 ◽

2007 ◽

Author(s):

Howard Fields

Keyword(s):

Receptor Antagonist ◽

Conditioned Place Preference ◽

Opioid Receptor ◽

Receptor Agonist ◽

Mu Opioid Receptor ◽

Place Preference ◽

Delta Opioid Receptor ◽

Bivalent Ligands ◽

Mu Opioid ◽

Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis

European Journal of Pharmacology ◽

10.1016/j.ejphar.2019.172702 ◽

2019 ◽

Vol 864 ◽

pp. 172702 ◽

Cited By ~ 8

Author(s):

Saadet Inan ◽

Alvaro Torres-Huerta ◽

Liselotte E. Jensen ◽

Nae J. Dun ◽

Alan Cowan

Keyword(s):

Contact Dermatitis ◽

Receptor Antagonist ◽

Opioid Receptor ◽

Receptor Agonist ◽

Mu Opioid Receptor ◽

Kappa Opioid Receptor ◽

Kappa Opioid ◽

Mu Opioid ◽

Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores

European Journal of Pharmacology ◽

10.1016/j.ejphar.2007.02.040 ◽

2007 ◽

Vol 566 (1-3) ◽

pp. 75-82 ◽

Cited By ~ 54

Author(s):

Natalie R. Lenard ◽

David J. Daniels ◽

Philip S. Portoghese ◽

Sandra C. Roerig

Keyword(s):

Receptor Antagonist ◽

Conditioned Place Preference ◽

Opioid Receptor ◽

Receptor Agonist ◽

Mu Opioid Receptor ◽

Place Preference ◽

Delta Opioid Receptor ◽

Bivalent Ligands ◽

Mu Opioid ◽

244 Efficacy of kappa-opioid receptor agonist and mu-opioid receptor antagonist to treat itch in imiquimod-induced psoriasis-like dermatitis model

Journal of Investigative Dermatology ◽

10.1016/j.jid.2016.06.264 ◽

2016 ◽

Vol 136 (9) ◽

pp. S203

Author(s):

N. Takahashi ◽

M. Tominaga ◽

Y. Kamata ◽

Y. Umehara ◽

H. Matsuda ◽

...

Keyword(s):

Receptor Antagonist ◽

Opioid Receptor ◽

Receptor Agonist ◽

Mu Opioid Receptor ◽

Kappa Opioid Receptor ◽

Kappa Opioid ◽

Mu Opioid ◽

Receptor Binding Properties and Antinociceptive Effects of Chimeric Peptides Consisting of a μ-Opioid Receptor Agonist and an ORL1 Receptor Antagonist

Biological and Pharmaceutical Bulletin ◽

10.1248/bpb.30.1260 ◽

2007 ◽

Vol 30 (7) ◽

pp. 1260-1264 ◽

Cited By ~ 9

Author(s):

Susumu Kawano ◽

Risa Ito ◽

Miharu Nishiyama ◽

Mai Kubo ◽

Tomoko Matsushima ◽

...

Keyword(s):

Receptor Antagonist ◽

Opioid Receptor ◽

Receptor Binding ◽

Receptor Agonist ◽

Mu Opioid Receptor ◽

Binding Properties ◽

Mu Opioid ◽

Opioid Receptor Agonist ◽

Antinociceptive Effects ◽

Chimeric Peptides

Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities

Bioorganic & Medicinal Chemistry Letters ◽

10.1016/j.bmcl.2015.06.030 ◽

2015 ◽

Vol 25 (17) ◽

pp. 3716-3720 ◽

Cited By ~ 8

Author(s):

Padma Nair ◽

Takashi Yamamoto ◽

Scott Cowell ◽

Vinod Kulkarni ◽

Sharif Moye ◽

...

Keyword(s):

Receptor Antagonist ◽

Opioid Receptor ◽

Receptor Agonist ◽

Mu Opioid Receptor ◽

Mu Opioid ◽

Neurokinin 1 Receptor ◽

Opioid Receptor Agonist ◽

Neurokinin 1 ◽

Multifunctional Ligands

Faculty Opinions recommendation of The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9987957.10722055 ◽

2011 ◽

Author(s):

Alfredo Berardelli ◽

Antonio Suppa

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Receptor Antagonist ◽

Opioid Receptor ◽

Mu Opioid Receptor ◽

Mu Opioid ◽

Macaque Model ◽

Opioid Receptor Antagonist

Itching-like behavior: A common effect of the kappa opioid receptor antagonist 5'-guanidinonaltrindole and the biased kappa opioid receptor agonist 6'-guanidinonaltrindole in mice

Medicine in Drug Discovery ◽

10.1016/j.medidd.2021.100097 ◽

2021 ◽

pp. 100097

Author(s):

Alan Cowan ◽

Lee-Yuan Liu-Chen ◽

Saadet Inan

Keyword(s):

Receptor Antagonist ◽

Opioid Receptor ◽

Receptor Agonist ◽

Kappa Opioid Receptor ◽

Kappa Opioid ◽

Common Effect ◽

Naloxonazine, a specific mu-opioid receptor antagonist, attenuates the increment of locomotor activity induced by acute methamphetamine in mice

Toxicology Letters ◽

10.1016/j.toxlet.2012.04.022 ◽

2012 ◽

Vol 212 (1) ◽

pp. 61-65 ◽

Cited By ~ 5

Author(s):

Chih-Cheng Chien ◽

Yih-Jing Lee ◽

Lir-Wan Fan ◽

Ing-Kang Ho ◽

Lu-Tai Tien

Keyword(s):

Locomotor Activity ◽

Receptor Antagonist ◽

Opioid Receptor ◽

Mu Opioid Receptor ◽

Mu Opioid ◽

Opioid Receptor Antagonist